CN104771518B - Pharmaceutical composition for resisting inflammation and treating or assisting in treating swine fever and preparation method thereof - Google Patents
Pharmaceutical composition for resisting inflammation and treating or assisting in treating swine fever and preparation method thereof Download PDFInfo
- Publication number
- CN104771518B CN104771518B CN201510217887.4A CN201510217887A CN104771518B CN 104771518 B CN104771518 B CN 104771518B CN 201510217887 A CN201510217887 A CN 201510217887A CN 104771518 B CN104771518 B CN 104771518B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- treating
- parts
- preparation
- fever
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010037660 Pyrexia Diseases 0.000 title claims abstract description 38
- 241000282898 Sus scrofa Species 0.000 title claims abstract description 28
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 206010061218 Inflammation Diseases 0.000 title abstract description 9
- 230000004054 inflammatory process Effects 0.000 title abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 41
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 20
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 19
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 19
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 19
- 235000011477 liquorice Nutrition 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 17
- 239000000843 powder Substances 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 4
- 229940079593 drug Drugs 0.000 claims description 31
- 241000245665 Taraxacum Species 0.000 claims description 19
- 240000006688 Telosma cordata Species 0.000 claims description 16
- 235000017352 Telosma cordata Nutrition 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 5
- 238000009098 adjuvant therapy Methods 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 241000282887 Suidae Species 0.000 abstract description 10
- 230000036760 body temperature Effects 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 206010024642 Listless Diseases 0.000 abstract description 2
- 206010061428 decreased appetite Diseases 0.000 abstract description 2
- 230000009545 invasion Effects 0.000 abstract description 2
- 208000017971 listlessness Diseases 0.000 abstract description 2
- 230000002085 persistent effect Effects 0.000 abstract description 2
- 230000035922 thirst Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 210000002700 urine Anatomy 0.000 abstract description 2
- 208000032841 Bulimia Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 208000008203 tachypnea Diseases 0.000 abstract 1
- 206010043089 tachypnoea Diseases 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 16
- AYIRNRDRBQJXIF-NXEZZACHSA-N (-)-Florfenicol Chemical group CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)C=C1 AYIRNRDRBQJXIF-NXEZZACHSA-N 0.000 description 11
- 239000013068 control sample Substances 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 241000334154 Isatis tinctoria Species 0.000 description 4
- 208000021760 high fever Diseases 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 239000003777 experimental drug Substances 0.000 description 2
- 229960003760 florfenicol Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010028470 Mycoplasma infections Diseases 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000024949 Swine Erysipelas Diseases 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000032625 disorder of ear Diseases 0.000 description 1
- 230000001584 effect on egg Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a pharmaceutical composition for resisting inflammation and treating or assisting in treating swine fever and a preparation method thereof. The medicine composition is prepared by taking dandelion, folium isatidis, herba violae and liquorice as raw materials; the preparation method comprises extracting the raw materials or medicinal powder with water, and concentrating. The invention also provides application of the pharmaceutical composition in preparing medicaments for resisting inflammation, treating or assisting in treating swine fever. The pharmaceutical composition is administrated in the form of decoction, has good treatment effects on listlessness, body temperature rise, tachypnea, thirst and bulimia, inappetence, short and yellow urine, persistent fever, general redness and other clinical symptoms of pigs caused by accumulated damp-heat and gradual invasion of toxic heat into wei-qi, ying-qi and blood, and has a cure rate of over 70 percent and strong research value.
Description
Technical Field
The invention relates to a pharmaceutical composition for anti-inflammation, treatment or adjuvant treatment of swine fever, a preparation method and application thereof, belonging to the field of medicines.
Background
Veterinary clinical practice has shown that abnormal body temperature is one of the important symptoms of disturbed pig physiology. The normal body temperature of the pig is 38-40 ℃, and when the body temperature continuously exceeds more than 40 ℃, the pig is febrile. The swine fever disease is one of the common diseases in the pig farm at present, causes of body temperature rise are many, and clinically, the swine fever disease can be divided into infectious fever and non-infectious fever, wherein the infectious fever is the most common, various pathogens (such as bacteria, viruses, mycoplasma, chlamydia, rickettsia, spirochete, fungi and parasites) can cause fever, and acute infectious diseases play an important role in the infectious fever, and the common infectious diseases such as swine fever, swine erysipelas, swine streptococcosis, swine toxoplasmosis, swine eperythrozoonosis and the like all have high fever and systemic symptoms of different degrees.
Fever is a physiological method for resisting diseases of the body within a certain limit, short-time moderate fever is beneficial to the body, but high fever lasts for a long time and causes great damage to the body, so that the catabolism of the body is accelerated, the nutrient substances are excessively consumed, the digestive function is disordered, the body is thinned, the resisting force is reduced, the central nervous system and the blood circulation system are damaged, and the sick pigs are mentally depressed to cause coma, heart failure and other serious consequences.
Aiming at the complexity of pathogenic factors causing fever at present, the traditional western medicine treatment method plays an important role in treating fever diseases, but the negative effects are increasingly prominent, such as fever rebound caused by blind use of antipyretics, generation of bacterial drug resistance caused by use of a large amount of antibiotics, increasingly poor treatment effect, and more serious food safety problems caused by antibiotic residues. Meanwhile, the state forbids antiviral medicines, so that a plurality of serious fever diseases are clinically treated by veterinarians in a state of no medicine and medical treatment.
The traditional Chinese veterinary medicine has a unique theoretical system when used for treating the pig fever diseases, and the traditional Chinese veterinary medicine theories think that the pig fever is caused by exogenous wind-heat, the pathogenic factors compete with each other, the defense-exterior is out of favor, the defense-yang is blocked, and the heat cannot be released, so that the sick animals are aversion to cold and generate heat, if the pathogenic factors enter the interior, the heat is generated to turn into fire, and the interior heat is exuberant, so that the heat enters the qi system or invades nutrient-blood. A large number of modern researches show that a large number of traditional Chinese medicines have the effects of clearing heat, removing toxicity, resisting bacteria and viruses and have unique advantages in treating certain febrile diseases.
Aiming at the current situations of complex etiology and serious illness state of the swine fever disease, the swine fever disease is treated by four medicinal materials including folium isatidis, dandelion, herba violae and liquorice in a formula, the folium isatidis is a monarch drug for clearing heat and removing toxicity, the dandelion and the herba violae are used for clearing heat and removing toxicity, and resolving carbuncle and dissipating stagnation, and the liquorice is an assistant drug for clearing heat and removing toxicity and harmonizing the other drugs. The medicines are combined to play the roles of clearing heat and removing toxicity, cooling blood and relieving swelling.
CN201310264823.0 discloses a micro-powder granule for treating swine fever, which comprises the following components: 40 parts of folium isatidis, 38 parts of dandelion, 12 parts of Chinese violet, 6 parts of liquorice and 4 parts of sucrose. The invention has the defects that the good antipyretic and anti-inflammatory effects can be obtained only by carrying out micro-powder treatment on part of medicinal materials in the prescription, the process steps are complicated, and the production cost is increased.
Disclosure of Invention
The technical scheme of the invention is to provide a pharmaceutical composition for anti-inflammation, treatment or adjuvant treatment of swine fever, a preparation method and application thereof.
The invention provides a pharmaceutical composition for resisting inflammation, treating or assisting in treating swine fever, which is prepared from the following raw material medicines in parts by weight:
60-120 parts of dandelion, 30-60 parts of folium isatidis, 30-60 parts of Chinese violet and 10-20 parts of liquorice.
Preferably, the weight ratio of the raw material medicines is as follows:
60 parts of dandelion, 30 parts of folium isatidis, 30 parts of Chinese violet and 10 parts of liquorice; or
60 parts of dandelion, 60 parts of folium isatidis, 60 parts of Chinese violet and 10 parts of liquorice; or
120 parts of dandelion, 30 parts of folium isatidis, 30 parts of Chinese violet and 10 parts of liquorice; or
120 parts of dandelion, 30 parts of folium isatidis, 60 parts of Chinese violet and 10 parts of liquorice.
Further preferably, the weight ratio of the raw material medicines is as follows:
120 parts of dandelion, 30 parts of folium isatidis, 60 parts of Chinese violet and 10 parts of liquorice.
The pharmaceutical composition is a preparation prepared by taking dandelion, folium isatidis, herba violae and liquorice as active ingredients and adding pharmaceutically acceptable auxiliary materials.
Wherein the preparation is decoction, powder, granules, mixture, tablets or capsules.
The invention provides a preparation method of a pharmaceutical composition for anti-inflammation, treatment or adjuvant treatment of swine fever, which is prepared by adding 20 times of water into bulk drugs or bulk drug powder in the amount of a prescription, extracting for 2 times, 1 hour each time, and concentrating under reduced pressure to a solution containing 1g/ml of the bulk drugs.
The invention also provides application of the pharmaceutical composition in preparing medicaments for resisting inflammation, treating or assisting in treating swine fever.
According to the pharmaceutical composition prepared by the invention, because the specific gravity of the dandelion and the Chinese violet which have strong heat-clearing and detoxifying effects in the prescription is increased, the pharmaceutical composition can be prepared by a conventional method, also has strong anti-inflammatory effect and good curative effect of treating high fever, so that the process steps are simplified, and the production cost is reduced.
The pharmaceutical composition prepared by the invention is administrated in the form of decoction, has good treatment effects on the clinical symptoms of listlessness, body temperature rise, shortness of breath, thirst, anorexia, short and yellow urine, persistent fever, systemic redness and the like of pigs caused by accumulated damp-heat and gradual invasion of toxic heat into wei-qi, ying-nutrient and blood, and has the cure rate of over 70 percent and strong research value.
The above-mentioned contents of the present invention will be further described in detail by the following specific embodiments of examples. This should not be construed as limiting the scope of the above-described subject matter of the invention to the following examples. Various substitutions and alterations according to the general knowledge and conventional practice in the art without departing from the technical idea of the invention are included in the scope of the invention.
Detailed Description
Example 1A pharmaceutical composition for the treatment of fever in pigs
Weighing the following raw materials (g):
60g of dandelion, 30g of dyers woad leaf, 30g of Chinese violet and 10g of liquorice
The preparation method comprises the following steps: weighing 20 times of bulk drug of the prescription amount, extracting for 2 times with water for 1 hour each time, and concentrating under reduced pressure to obtain solution containing 1g/ml of bulk drug for later use.
Example 2A pharmaceutical composition for the treatment of fever in pigs
Weighing the following raw materials (g):
60g of dandelion, 60g of dyers woad leaf, 60g of Chinese violet and 10g of liquorice
The preparation method is the same as example 1.
Example 3A pharmaceutical composition for the treatment of fever in pigs
Weighing the following raw materials (g):
120g of dandelion, 30g of dyers woad leaf, 30g of Chinese violet and 10g of liquorice
The preparation method is the same as example 1.
Example 4A pharmaceutical composition for the treatment of fever in pigs
Weighing the following raw materials (g):
120g of dandelion, 30g of dyers woad leaf, 60g of Chinese violet and 10g of liquorice
The preparation method is the same as example 1.
The beneficial effects of the present invention are demonstrated by pharmacodynamic tests below.
Experimental example 1 anti-inflammatory comparative test of the drug of the present invention
(1) Experimental drugs
Sample 1 drug prepared according to example 1
Sample 2 drug prepared according to example 2
Sample 3 drug prepared according to example 3
Sample 4 drug prepared according to example 4
The comparison sample 5 is prepared from the following raw material medicines according to the proportion disclosed in the patent application number 201310264823.0: weighing raw material medicines of 38g of dandelion, 40g of folium isatidis, 12g of Chinese violet and 6g of liquorice, extracting with 20 times of water for 2 times, 1 hour each time, and concentrating under reduced pressure to obtain a solution containing 1g/ml of the raw material medicines for later use to prepare a control sample 5.
140 healthy Kunming mice with the weight of 18-22 g are selected, the male and female parts of the mice are divided into 7 groups at random, each group comprises 20 mice, wherein a control group is perfused with sterile physiological saline solution, a positive control group is perfused with dexamethasone drug solution (the concentration of the aqueous solution is 0.5 mg/ml), the other five groups are respectively administered with the solutions of samples 1, 2, 3 and 4 and the control sample 5, the administration dose is 5g/kgb.w, and the administration is carried out 1 time a day for 5 days. After the last administration for 1h, 0.03 ml/mouse of 10% fresh egg white solution was injected under the plantar tendon of the right hind foot. After 3h, the patient was sacrificed and both feet were removed from the same position and weighed separately. The difference between the weights of the two feet is taken as the swelling degree.
TABLE 1 Effect on egg white induced swelling of mouse feet (x + -SD, n ═ 20)
Note: p <0.05 compared to control group, P <0.01 compared to control group
The test results show that the positive control group, the samples 3 and 4 have extremely obvious difference (P <0.01) compared with the normal saline group, and the samples 1 and 2 have obvious difference (P <0.05) compared with the normal saline group, so that the samples 1 to 4 have obvious anti-inflammatory effect; in addition, the anti-inflammatory effects of the samples 1-4 groups are all better than that of the control sample 5 group, especially the anti-inflammatory effects of the samples 3 and 4 groups are strongest, and compared with the control sample 5, the inhibition rate is improved by more than two times; the sample 4 group was optimized and superior to the positive drug dexamethasone group.
Experimental example 2 clinical trial for treating swine fever
(1) Experimental drugs
Sample A drug prepared according to example 3
Sample B the drug prepared according to example 4
The comparison sample C is prepared from the following raw material medicines according to the proportion disclosed in the patent application No. 201310264823.0: weighing raw material medicines of 38g of dandelion, 40g of folium isatidis, 12g of Chinese violet and 6g of liquorice, extracting with 20 times of water for 2 times, 1 hour each time, and concentrating under reduced pressure to obtain a solution containing 1g/ml of the raw material for later use to prepare a control sample C.
(2) Experimental animal selection and grouping
Selecting pigs with clinical body temperature rising to 40-42 ℃ and confirmed blue ear disease as clinical test subjects, selecting diseased pigs 150, dividing into 5 groups, each group comprising 30, and dividing into a sample A + florfenicol group, a sample B + florfenicol group, a control sample C + florfenicol group, a florfenicol group and a blank control group.
(3) Method and amount of administration
Sample A, B and control sample C groups were fed with sample A, B and control sample C, respectively, concurrently with florfenicol treatment, with the florfenicol group being given florfenicol medication only and the blank control group not being given any medication. The administration was continued for 7 days.
(4) Test index and method
After the administration is finished, the cure conditions of the sick pigs of each group are observed, and indexes such as cure rate, death rate and the like are statistically analyzed.
(5) Test results and analysis
TABLE 2 clinical trial test results
Clinical verification test results show that the mortality rates of a control group, a florfenicol group, a sample A, B group and a control sample C group are respectively 86.7%, 40.0%, 13.3%, 3.3% and 30%, compared with the control group, the mortality rate of an administration group is greatly reduced, compared with the control group, the sample A, B group has a remarkable curative effect of treating porcine reproductive and respiratory syndrome, the mortality rate of a porcine reproductive and respiratory syndrome pig can be reduced to a lower level by combining the florfenicol group with the florfenicol group, the curative effect of the fever disease treatment by the composition is verified, meanwhile, the test results show that the curative effect of the sample B is the best, the cure rate of the florfenicol group with the porcine reproductive and respiratory syndrome can reach 96.7%, and the curative effect is remarkably superior to that of the control sample C, and the pharmaceutical composition prepared by the method is proved to have a remarkable curative effect of treating high fever.
Claims (6)
1. A pharmaceutical composition for treating or assisting in treating swine fever is characterized in that: the traditional Chinese medicine is prepared from the following raw materials in parts by weight:
120 parts of dandelion, 30 parts of folium isatidis, 60 parts of Chinese violet and 10 parts of liquorice.
2. The pharmaceutical composition of claim 1, wherein: the preparation is prepared by taking dandelion, folium isatidis, Chinese violet and liquorice as active ingredients and adding pharmaceutically acceptable auxiliary materials.
3. The pharmaceutical composition of claim 2, wherein: the preparation is decoction, powder, granules, mixture, tablets or capsules.
4. A process for preparing a pharmaceutical composition according to any one of claims 1 to 3, characterized in that: taking the bulk drugs or the raw material powder according to the prescription amount, adding water for extraction, and concentrating to obtain the traditional Chinese medicine.
5. The method of claim 4, wherein: extracting with 20 times of water for 2 times, each for 1 hr, and concentrating under reduced pressure to obtain solution containing 1g/ml of medicinal material.
6. Use of the pharmaceutical composition of any one of claims 1-3 in the preparation of a medicament for the treatment or adjuvant treatment of swine fever.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510217887.4A CN104771518B (en) | 2015-04-30 | 2015-04-30 | Pharmaceutical composition for resisting inflammation and treating or assisting in treating swine fever and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510217887.4A CN104771518B (en) | 2015-04-30 | 2015-04-30 | Pharmaceutical composition for resisting inflammation and treating or assisting in treating swine fever and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104771518A CN104771518A (en) | 2015-07-15 |
| CN104771518B true CN104771518B (en) | 2020-06-23 |
Family
ID=53613501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510217887.4A Expired - Fee Related CN104771518B (en) | 2015-04-30 | 2015-04-30 | Pharmaceutical composition for resisting inflammation and treating or assisting in treating swine fever and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104771518B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106361815A (en) * | 2016-10-31 | 2017-02-01 | 成都乾坤动物药业股份有限公司 | Ammophila-Arenaria-containing pharmaceutical composition for treating swine fever, and preparation method and application thereof |
| CN115969938B (en) * | 2022-10-11 | 2024-03-26 | 华中农业大学 | Preparation method of traditional Chinese medicine prescription for inhibiting IGF-1R transcription level up-regulation caused by streptococcus suis infection |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103285176A (en) * | 2013-06-27 | 2013-09-11 | 成都乾坤动物药业有限公司 | Micro-powder granules for treating fever disease of pigs and preparation process thereof |
| CN104155383A (en) * | 2014-08-27 | 2014-11-19 | 成都乾坤动物药业有限公司 | Detection method of dandelion and viola philippica granules |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2006008802A1 (en) * | 2004-07-20 | 2008-07-31 | 株式会社栃本天海堂 | Herbal medicine for domestic animals |
-
2015
- 2015-04-30 CN CN201510217887.4A patent/CN104771518B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103285176A (en) * | 2013-06-27 | 2013-09-11 | 成都乾坤动物药业有限公司 | Micro-powder granules for treating fever disease of pigs and preparation process thereof |
| CN104155383A (en) * | 2014-08-27 | 2014-11-19 | 成都乾坤动物药业有限公司 | Detection method of dandelion and viola philippica granules |
Non-Patent Citations (1)
| Title |
|---|
| 消炎退热胶囊的质量标准研究;陈学松;《中成药》;20090731;第31卷(第7期);第1140-1142页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104771518A (en) | 2015-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101512495B1 (en) | Applications of arctigenin in formulating medicines for preventing or treating diseases related to red blood cell reduction | |
| CN103006892A (en) | Medicine composition for preventing and treating porcine viral diseases, and premix and batch with composition | |
| JP2011526255A (en) | Natural allicin tablet and preparation method thereof | |
| CN104771518B (en) | Pharmaceutical composition for resisting inflammation and treating or assisting in treating swine fever and preparation method thereof | |
| CN102895326B (en) | Traditional Chinese medicine composition for treating infantile common cold and preparation method for traditional Chinese medicine composition | |
| CN102526568B (en) | Traditional Chinese medicine compound composition | |
| CN105688157A (en) | Traditional Chinese medicine compound preparation for resisting swine influenza virus and preparing method thereof | |
| CN111700998A (en) | Application of compound Chinese patent medicine in treating pneumonia COVID-19 infected by novel coronavirus | |
| CN113577187B (en) | Traditional Chinese medicine composition and traditional Chinese medicine extract for treating influenza and preparation method and application thereof | |
| CN105770054A (en) | Pharmaceutical composition for preventing and treating chicken coccocidiosis, additive and feed | |
| CN101780064B (en) | New application of p-hydroxyl cinnamic acid | |
| CN102614294A (en) | Compound amoxicillin suspension injection and preparation method thereof | |
| CN102293764B (en) | New application of p-hydroxycinnamic acid | |
| CN101721437B (en) | Preparation method of medicine composition used for treating chronic pharyngitis | |
| CN103055002A (en) | Composition for treating respiratory disease of poultry and preparation method thereof | |
| CN115887546B (en) | Pharmaceutical composition for resisting coccidium and application | |
| CN109731044B (en) | Traditional Chinese medicine compound granule for treating intestinal infection of poultry and preparation method thereof | |
| CN101926846A (en) | Medicinal composition for treating pullorum disease and preparation method thereof | |
| Peter et al. | Cytoprotective effects of ethanolic extract of Vernonium amygdalina leaves on alloxan induced hepato-toxicity in albino wistar rats | |
| CN107296858B (en) | Antibacterial infection pharmaceutical composition and application thereof | |
| CN106581027B (en) | Compound and pharmaceutical application, composition and preparation thereof | |
| CN104188992B (en) | A kind of pharmaceutical composition for treating nephrotic syndrome | |
| CN116036195A (en) | A Chinese medicinal unguent for treating foot and mouth disease of livestock, and its preparation method | |
| CN104586826B (en) | Levocarnitine and its derivative are preparing the application in treating or preventing idiopathic pulmonary fibrosis drug | |
| CN114533710A (en) | Application of curcumin in preparation of medicine for preventing and treating reproductive system injury caused by ionizing radiation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 611130, No. 259, Golden Road, Chengdu science and Technology Industrial Development Zone, Wenjiang District, Sichuan, China Applicant after: CHENGDU QIANKUN VETERINARY PHARMACEUTICAL CO.,LTD. Address before: 611130, No. 259, Jin Gong Road, Chengdu science and Technology Industrial Development Zone, Chengdu Strait, Wenjiang District, Sichuan, China Applicant before: CHENGDU QIANKUN VETERINARY PHARMACEUTICAL Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190910 Address after: Wenjiang District of Chengdu City, the 610000 Daytona bridge in Sichuan Province Road No. 392 Applicant after: CHENGDU VOCATIONAL College OF AGRICULTURAL SCIENCE AND TECHNOLOGY Applicant after: CHENGDU QIANKUN VETERINARY PHARMACEUTICAL CO.,LTD. Address before: 611130, No. 259, Golden Road, Chengdu science and Technology Industrial Development Zone, Wenjiang District, Sichuan, China Applicant before: CHENGDU QIANKUN VETERINARY PHARMACEUTICAL CO.,LTD. |
|
| TA01 | Transfer of patent application right | ||
| AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20200501 |
|
| AD01 | Patent right deemed abandoned | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| RR01 | Reinstatement of patent right |
Former decision: deemed abandonment of patent right Former decision publication date: 20200501 |
|
| RR01 | Reinstatement of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200623 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |